Gossamer Bio
GOSS
118 hedge funds and large institutions have $225M invested in Gossamer Bio in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 33 reducing their positions, and 58 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 33
22% more capital inflows, than outflows
Capital inflows: $423M | Capital outflows: $346M
19.12% more ownership
Funds ownership: 90.7% → 109.81% (+19%)
0% more call options, than puts
Call options by funds: $857K | Put options by funds: $857K
25% less funds holding
Funds holding: 157 → 118 (-39)
66% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 58
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$198M |
| 2 |
Millennium Management
New York
|
+$27.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$22.1M |
| 4 |
Rafferty Asset Management
New York
|
+$20.9M |
| 5 |
Morgan Stanley
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$49.8M |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$38.3M |
| 3 |
VR Adviser
New York
|
-$20.9M |
| 4 |
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$20.1M |
| 5 |
Omega Fund Management
Boston,
Massachusetts
|
-$18M |
GOSS Hedge Fund Activity: Q4 2022 in Review
118 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q4 2022, worth a combined $225M — down 78% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of GOSS and 20 opened new positions — a net loss of 38 holders — while 33 trimmed existing stakes and 50 added.
The largest buyer was State Street, adding an estimated $198M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $49.8M sold.
- 118 institutional investors held Gossamer Bio (GOSS) as of Q4 2022, down from 157 in Q3 2022.
- Funds reported $225M of Gossamer Bio stock for Q4 2022, down 78% quarter-over-quarter.
- 20 funds opened new Gossamer Bio positions in Q4 2022 and 58 closed out, a net change of -38 holders.
- The largest Gossamer Bio buyer in Q4 2022 was State Street, an estimated $198M added.
- The largest Gossamer Bio seller in Q4 2022 was EcoR1 Capital, an estimated $49.8M sold.
Based on aggregated 13F filings for Q4 2022.